SLC5A2 and Hypoglycemia: These findings were achieved with lower insulin concentrations than the placebo and without an increase in hypoglycemia.21,27 Also, a meta-analysis study showed that the SGLT2 inhibitor treatment, as an adjunct to insulin therapy, remarkably decreased the A1C in comparison with placebo.